9.5-Year Follow-Up on Effects of Rituximab in RA PatientsProHealthThe drug rituximab is used in combination with methotrexate to control autoimmune damage to RA patients' joints by reducing levels of a specific immune B-cell that attacks them. The …
Halozyme Reports Third Quarter 2012 Financial ResultsSacramento Bee"We are pleased with the clinical data from the subcutaneous MabThera (rituximab) trials which should enable filing of the marketing application in Europe later this year," sa…
Cambridge NewsPatient's life-saving drugs too expensive, family toldCambridge NewsHis wife Carol Burling, 54, got in touch with the News after it featured the story of schoolgirl Zoe Gilbert, who has the same condition and is currently receiving a …
TG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and …Equities.comThe following abstracts were accepted for presentation: Ublituximab (TG-1101), an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Tha…
Cambridge NewsZoe starts treatment for bone marrow ailmentCambridge NewsDoctors are treating the Impington Village College student with anti-thymocyte globulin (ATG) – an infusion of horse antibodies as they have not found a bone marrow donor that ma…
Avonex Share of First-Line Therapy Among Multiple Sclerosis Patients has …MarketWatch (press release)Patient profiles for the eight DMAs in late clinical development (Aubagio, BG-12, alemtuzumab, PEG-Avonex, Copaxone 40mg 3x weekly, daclizumab, laqui…
US Patents Awarded to Inventors in Maryland (Nov. 5)Equities.comIn particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other…
News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans …The Pharma LetterThe Sandoz follicular lymphoma Phase III clinical trial for biosimilar monoclonal antibody rituximab, a biosimilar of Roche's Rituxan/MabThera (which …
Emergent BioSolutions initiates Phase Ib chronic lymphocytic leukemia studyEquities.comNov 02, 2012 (Datamonitor via COMTEX) — Emergent BioSolutions Inc., a biopharmaceutical company, has announced the initiation of a Phase Ib study, or Protocol 16009…
SEP : l'alemtuzumab pourrait bientôt jouer dans la même cour que le TysabriMedscape FranceD'autres anticorps monoclonaux sont actuellement en développement à un stade moins avancé, au rang desquels l'ocrelizumab, et le daclizumab. Mais…